Aggressive nodal or extranodal mature (peripheral) T-cell lymphomas that do not belong to the better defined entities of the remainder of mature T-cell lymphomas. This category includes the following ...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The documentation for peripheral T-cell lymphoma, not otherwise specified is limited due to its rarity and the complexity of its clinical presentation. As this condition affects a relatively small population, comprehensive clinical studies and systematic documentation have been scarce. This can lead to feelings of isolation and uncertainty for patients and families seeking information.
To navigate your journey with PTCL-NOS, consider consulting a hematologist or oncologist with expertise in T-cell lymphomas. They can provide tailored treatment options and insights into ongoing clinical trials. You may also explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and support for rare diseases. Participating in clinical trials could provide access to cutting-edge therapies and contribute to the understanding of this condition.
There are several orphan drugs designated for PTCL-NOS, including Belinostat, cerdulatinib, and mogamulizumab, among others. These drugs are currently in various stages of development. Additionally, there are 14 active clinical trials investigating new treatment options and strategies for managing this condition. You can explore these trials at ClinicalTrials.gov by searching for 'peripheral T-cell lymphoma, not otherwise specified'.
Actionable guidance for navigating care for peripheral T-cell lymphoma, not otherwise specified
To navigate your journey with PTCL-NOS, consider consulting a hematologist or oncologist with expertise in T-cell lymphomas. They can provide tailored treatment options and insights into ongoing clinical trials. You may also explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and support for rare diseases. Participating in clinical trials could provide access to cutting-edge therapies and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 7 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.